INTRODUCTION: The aim of this study is to present a case of 44 years old woman with topiramate induced metabolic acidosis and kidney stones. MATERIALS AND METHODS: The laboratory features of topiramate caused renal tubular acidosis in blood and urine during topiramate treatment, with correction of metabolic acidosis by potassium citrate, and after topiramate withdrawal are presented. Differential diagnosis of all possible causes of metabolic acidosis is discussed. RESULTS: The results revealed negative base excess in extracellular fluid of - 9.2 mmol/L, low serum HCO3- concentration (18.6 mmol/L), trend to alkaline urine (pH 6.39) and low urine citrate concentration (0.3 mmol/24h). After topiramate withdrawal, all parameters of the internal environment normalized. CONCLUSIONS: This study has shown that long-term topiramate administration could induce metabolic acidosis and consequently urholithiasis. Thus, we could recommend testing blood acid base balance, urinary pH and citrates in patients taking topiramate and suffering from kidney stones.

Department of Clinical Biochemistry Tomas Bata Hospital in Zlín a s Zlín Czech Republic

Department of Urology Tomas Bata Hospital in Zlín a s Zlín Czech Republic

Medical Faculty of the University of Ostrava in Ostrava Ostrava Zábřeh Czech Republic

Zobrazit více v PubMed

European Association of Urology. Guidelines on Urolithiasis. Available at: http://uroweb.org/guideline/urolithiasis/. Accessed June 10th 2015.

Dell’Orto VG, Belotti EA, Goeggel-Simonetti B, Simonetti GD, Ramelli GP, Bianchetti MG, et al. Metabolic disturbances and renal stone promotion on treatment with topiramate: a systematic review. Br J Clin Pharmacol. 2014;77:958–64. 10.1111/bcp.12283 PubMed DOI PMC

Mirza N, Marson AG, Pirmohamed M. Effect of topiramate on acid–base balance: extent, mechanism and effects. Br J Clin Pharmacol. 2009;68:655–61. 10.1111/j.1365-2125.2009.03521.x PubMed DOI PMC

Welch BJ, Graybeal D, Moe OW, Maalouf NM, Sakhaee K. Biochemical and stone-risk profiles with topiramate treatment. Am J Kidney Dis. 2006;48:555–63. 10.1053/j.ajkd.2006.07.003 PubMed DOI

Shavit L, Ferraro PM, Johri N, Robertson W, Walsh SB, Moochhala S, et al. Effect of being overweight on urinary metabolic risk factors for kidney stone formation. Nephrol Dial Transplant. 2015;30:607–13. 10.1093/ndt/gfu350 PubMed DOI

Fernández-de Orueta L, Esteban-Fernández J, Aichner HF, Casillas-Villamor A, Rodríguez-Álvarez S. Topiramate-induced metabolic acidosis: a case study. Nefrologia. 2012;32:403–4. PubMed

Burmeister JE, Pereira RR, Hartke EM, Kreuz M. Topiramate and severe metabolic acidosis: case report. Arq Neuropsiquiatr. 2005;63:532–4. 10.1590/S0004-282X2005000300032 PubMed DOI

Maalouf NM, Langston JP, Van Ness PC, Moe OW, Sakhaee K. Nephrolithiasis in topiramate users. Urol Res. 2011;39:303–7. 10.1007/s00240-010-0347-5 PubMed DOI PMC

Faught E. Review of United States and European clinical trials of zonisamide in the treatment of refractory partial-onset seizures. Seizure. 2004;13:S59–65. 10.1016/j.seizure.2004.04.009 PubMed DOI

Jhagroo RA, Wertheim ML, Penniston KL. Alkali replacement raises urinary citrate excretion in patients with topiramate‐induced hypocitraturia. Br J Clin Pharmacol. 2016;81:131–6. 10.1111/bcp.12751 PubMed DOI PMC

Chen W, Abramowitz MK. Metabolic acidosis and the progression of chronic kidney disease. BMC Nephrol. 2014;15:55. 10.1186/1471-2369-15-55 PubMed DOI PMC

Lila AR, Sarathi V, Jagtap V, Bandgar T, Menon PS, Shah NS. Renal manifestations of primary hyperparathyroidism. Indian J Endocrinol Metab. 2012;16:258–62. 10.4103/2230-8210.93745 PubMed DOI PMC